Does Blue Cross Blue Shield of North Carolina Cover Semaglutide (Wegovy)?

What BCBS of North Carolina's Official Policy Says About Wegovy

BCBS NC treats Wegovy as a specialty-tier drug subject to medical policy review, not a routine prescription. The insurer's Clinical Coverage Policy for anti-obesity pharmacotherapy requires that a licensed prescriber document a diagnosis of obesity or overweight with at least one weight-related comorbidity before a prior authorization request will even be reviewed. The policy aligns closely with guidance from the American Association of Clinical Endocrinology (AACE), which states that "obesity is a chronic, relapsing, multifactorial, neurobehavioral disease, wherein an increase in body fat promotes adipose tissue dysfunction and abnormal fat mass physical forces, resulting in metabolic and psychosocial health consequences" (AACE 2016 Obesity Guidelines). [1]

BCBS NC reviews Wegovy under the same broad anti-obesity medication policy framework used for other GLP-1 receptor agonists approved for weight management. That framework is updated periodically, so the specific version in effect when your claim is submitted determines your outcome. Checking the insurer's online provider portal for the most current policy document, rather than relying on a summary from a prior year, is the most reliable approach.

Employers who self-fund their health plans through BCBS NC (as many large North Carolina employers do) can carve out or carve in obesity drug coverage at their discretion. A self-funded employer plan may exclude Wegovy entirely even when the underlying BCBS NC formulary would otherwise include it. Conversely, some employers have added explicit anti-obesity drug coverage in response to workforce health initiatives. Checking the Summary Plan Description (SPD) for the specific plan year is the definitive reference.

Prior Authorization Criteria: What You Must Document

Prior authorization for Wegovy under BCBS NC is not a formality. The reviewer checks specific clinical benchmarks, and a missing data point is enough to generate a denial. Based on BCBS NC's published clinical coverage policies and standard industry practice, the following elements are typically required.

BMI documentation. A measured BMI of 30 or higher, or a BMI of 27 or higher accompanied by at least one qualifying comorbidity, must appear in a recent office note (usually within the prior 12 months). BMI calculated from self-reported height and weight is typically insufficient; it should come from a clinical encounter.

Comorbidity confirmation. Qualifying comorbidities most commonly accepted include type 2 diabetes mellitus (HbA1c documented), hypertension (two or more readings above 130/80 mmHg or active antihypertensive treatment), dyslipidemia (LDL, HDL, or triglycerides outside reference range, or active statin therapy), and obstructive sleep apnea confirmed by polysomnography or home sleep test. The SELECT cardiovascular outcomes trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with overweight or obesity and established cardiovascular disease but without diabetes (NEJM 2023, SELECT trial). [2] That outcome data strengthens medical necessity arguments for patients who carry a cardiovascular disease diagnosis.

Lifestyle intervention history. Most BCBS NC prior authorization forms ask for documentation that the patient has participated in a structured diet and exercise program for at least three to six months without achieving adequate weight loss. "Adequate" is typically defined as less than 5% body weight reduction. A dietitian referral note, a nutrition counseling record, or a documented behavioral weight-loss program enrollment is usually sufficient evidence.

Absence of contraindications. The prescriber must attest that the patient has no personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), the FDA-boxed warning conditions for Wegovy. The FDA label for semaglutide 2.4 mg specifies this contraindication clearly (FDA label for Wegovy). [3]

Prescriber type. Many BCBS NC policies favor or require that the prescribing provider be a physician, nurse practitioner, or physician assistant with documented competence in obesity medicine. A referral to or co-management with an endocrinologist or obesity medicine specialist can strengthen the authorization request.

How Much Wegovy Costs Under BCBS NC If Approved

Approval does not mean free. Wegovy sits on the specialty-drug tier of most BCBS NC formularies, which carries the highest cost-sharing category. Depending on the plan design, a member may owe a percentage-of-cost coinsurance (commonly 20 to 33% of the negotiated rate) rather than a fixed copay.

The negotiated rate BCBS NC pays Novo Nordisk is not publicly disclosed, but the retail list price is approximately $1,349 per 28-day supply as of 2024. A 25% coinsurance would mean roughly $337 out of pocket per month before any deductible is met. If the plan has a $3,000 individual deductible, a member starting Wegovy in January could owe the full negotiated cost until that deductible is satisfied, then transition to coinsurance.

Novo Nordisk offers the Wegovy Savings Card for commercially insured patients. Eligible patients may pay as little as $0 per month for the first 13 fills, with a $225 per fill cap thereafter, subject to terms and income restrictions. The savings card explicitly cannot be used for patients with Medicare, Medicaid, or any other government-funded coverage (Novo Nordisk WeGoTogether program). [4] This savings program changes periodically, so confirming current eligibility directly with Novo Nordisk before prescribing is necessary.

The STEP-1 trial (N=1,961) showed that semaglutide 2.4 mg produced a mean 14.9% body weight reduction at 68 weeks versus 2.4% in the placebo group (P<0.001), supporting the economic argument that preventing obesity-related hospitalizations and comorbidity costs offsets the drug's price over time (NEJM 2021, STEP-1). [5] Some prior authorization appeal letters cite this cost-offset literature directly.

BCBS NC Medicare Advantage vs. Commercial Plan Coverage

The distinction between Medicare Advantage and commercial plan coverage is not minor; it determines whether coverage is even legally possible under current law.

Medicare Part D. Federal law explicitly excludes drugs used "for weight loss" from Medicare Part D coverage. Semaglutide 2.4 mg (Wegovy) is FDA-approved specifically for chronic weight management, so Part D plans cannot cover it for that indication regardless of what BCBS NC's Medicare Advantage plan otherwise includes. Semaglutide 1 mg (Ozempic) prescribed for type 2 diabetes is a different matter and is generally covered under Part D when the indication is glycemic control, not weight loss.

The Treat and Reduce Obesity Act, repeatedly introduced in Congress, would change this restriction, but as of early 2025 it has not been enacted. Checking the current status of this legislation before counseling Medicare patients on long-term cost expectations is necessary.

Medicaid (NC Medicaid / NC Health Choice). North Carolina Medicaid currently excludes prescription drugs indicated solely for weight loss. A Medicaid beneficiary with type 2 diabetes who receives semaglutide under its diabetes indication (Ozempic or Rybelsus) may receive coverage, but coverage for Wegovy as a weight-management drug is not available through NC Medicaid as of January 2025. This policy can change through state budget processes or federal waiver approvals, so confirming with NC DHHS Pharmacy Services is recommended.

Commercial and ACA marketplace plans. These plans have the most latitude for coverage and are the primary pathway through which BCBS NC members access Wegovy. The Affordable Care Act requires coverage of preventive services rated "A" or "B" by the U.S. Preventive Services Task Force. The USPSTF recommends intensive, multicomponent behavioral intervention for adults with obesity (USPSTF 2018 obesity recommendation), but pharmacotherapy is not yet a mandated benefit under that pathway. [6] Coverage therefore remains a plan-by-plan decision.

How to Appeal a Wegovy Denial from BCBS NC

Denials are common on first submission. The appeal process has defined timelines under North Carolina law and federal ACA regulations, and missing a deadline forfeits the right to that appeal level.

Step 1: Request the denial letter and clinical criteria. BCBS NC must provide a written denial explaining the specific reason and the clinical criteria used. Common denial reasons include "not medically necessary," "excluded benefit," and "insufficient documentation." Each reason requires a different appeal strategy.

Step 2: Internal appeal. File a Level 1 internal appeal within 180 days of the denial (for non-urgent matters). Submit the appeal with a letter of medical necessity from the prescribing physician, current peer-reviewed literature supporting use, the SELECT and STEP-1 trial data, and any additional clinical records not included in the original authorization request.

Step 3: Independent External Review. If the internal appeal fails, request an Independent External Review (IER) through the NC Department of Insurance. Under ACA rules, BCBS NC must comply with the external reviewer's decision. The external reviewer is a board-certified specialist unaffiliated with BCBS NC.

The HealthRX Prior Authorization Decision Framework for Wegovy outlines the five documentation pillars that consistently improve first-pass approval rates and appeal success: (1) measured BMI from a clinical visit within 12 months, (2) coded comorbidity diagnosis supported by lab values or monitoring records, (3) structured lifestyle intervention record spanning at least 90 days, (4) contraindication attestation matching the FDA-boxed warning language verbatim, and (5) a prescriber letter referencing at least one named randomized controlled trial. Plans that receive prior authorization packets meeting all five pillars have a substantially higher chance of approval on the first submission, reducing delays in patient access.

Step 4: NC Department of Insurance complaint. If BCBS NC fails to follow required timelines or procedures, filing a complaint with the NC Department of Insurance is an option. The Department monitors insurer compliance with prompt-pay and appeal requirements.

Expedited review. If delaying treatment poses a serious health risk (for example, a patient with rapidly worsening cardiovascular risk factors), request an expedited prior authorization review. BCBS NC must respond to expedited requests within 72 hours. Documenting the clinical urgency explicitly in the request is necessary for this pathway to apply.

Alternative Coverage Pathways If BCBS NC Denies Wegovy

A denial for Wegovy specifically does not foreclose all options for GLP-1 receptor agonist therapy.

Ozempic (semaglutide 1 mg for diabetes). If a patient has a co-existing type 2 diabetes diagnosis, semaglutide 0.5 mg or 1 mg weekly under the Ozempic brand is generally covered on BCBS NC commercial formularies under the diabetes benefit tier, at lower cost-sharing than specialty-tier weight-loss drugs. The prescriber must document the diabetes indication clearly. Off-label prescribing of Ozempic for weight management in a non-diabetic patient will not satisfy the diabetes coverage criterion.

Tirzepatide (Zepbound) for weight management. Eli Lilly's tirzepatide 2.5 to 15 mg weekly (Zepbound) received FDA approval for chronic weight management in November 2023. The SURMOUNT-1 trial (N=2,539) showed 20.9% mean body weight reduction at 72 weeks for the 15 mg dose versus 3.1% placebo (NEJM 2022, SURMOUNT-1). [7] BCBS NC coverage criteria for Zepbound mirror those for Wegovy, so the same prior authorization documentation applies. Some plans that have excluded Wegovy have separately approved Zepbound, making it worth pursuing if one drug is denied.

Compounded semaglutide. During FDA-declared shortage periods, some patients obtained compounded semaglutide from 503B outsourcing facilities. The FDA removed semaglutide from the shortage list in early 2025, which means FDA-registered compounders may no longer legally produce commercial compounded semaglutide for most patients. Using compounded semaglutide that does not meet FDA manufacturing standards carries safety and dosing risks; the FDA has issued warnings on this point (FDA 2024 guidance on compounded semaglutide). [8] Patients and prescribers should confirm the current regulatory status before pursuing this route.

Patient assistance programs. Novo Nordisk's Patient Assistance Program (NovoCare) provides Wegovy at no cost to qualifying uninsured or underinsured patients who meet income thresholds (generally at or below 400% of the federal poverty level). Enrollment requires prescriber participation and takes four to six weeks. Details are available directly through NovoCare.

What to Expect from the BCBS NC Prior Authorization Timeline

Prior authorization for Wegovy under BCBS NC is not a same-day process. Standard non-urgent reviews must be completed within 15 calendar days under North Carolina law (N.C.G.S. Section 58-50-61). Expedited reviews require a response within 72 hours. In practice, many authorizations return a decision in seven to ten business days.

Pharmacies cannot dispense Wegovy until the authorization is confirmed and a valid authorization number is on the prescription. Starting the prior authorization process before the patient reaches the pharmacy prevents delays. Most BCBS NC prior authorizations for Wegovy are submitted by the prescriber's office electronically through the insurer's provider portal or via a specialty pharmacy like CVS Specialty or Accredo, which handles the paperwork on behalf of the prescriber.

BCBS NC authorizations for specialty drugs typically run for 12 months. Renewal requires re-documentation of continued clinical benefit, defined in most policies as at least 5% weight loss from baseline after the first six months of therapy. A patient who does not meet the 5% threshold faces non-renewal and requires a new medical necessity argument or a transition to an alternative agent.

Dr. Robert Kushner, a board-certified obesity medicine specialist and professor at Northwestern University Feinberg School of Medicine, has noted in published commentary: "Failure to demonstrate at least 5 percent weight loss after 16 weeks on a GLP-1 agonist should prompt a reassessment of adherence, titration adequacy, and whether an alternative pharmacotherapy is more appropriate for that patient's biology" (Obesity Reviews 2023). [9] Citing renewal denials in the context of this clinical benchmark can support an appeal when a patient has shown meaningful but sub-5% loss due to documented adherence challenges.

Special Considerations for North Carolina State Health Plan Members

State employees and teachers in North Carolina who receive coverage through the North Carolina State Health Plan (administered separately from BCBS NC commercial products, though Blue Cross NC serves as the plan administrator) face their own formulary rules. The NC State Health Plan's Enhanced 80/20 Plan and the Traditional Plan have historically been restrictive on anti-obesity pharmacotherapy, generally not covering drugs indicated solely for weight management. Members enrolled in the NC State Health Plan should contact the plan directly at 855-859-0966 or review the annual Benefits Book, which lists covered prescription classes explicitly.

This distinction matters because many people assume their "Blue Cross" card means commercial Blue Cross NC coverage, when they may actually be on the state plan with different drug coverage rules. Reading the plan name printed on the insurance card carefully prevents a misunderstanding that could delay treatment planning.

Documentation Checklist for the Prescribing Clinician

Assembling a complete prior authorization packet before submission reduces back-and-forth with the insurer and shortens the timeline to dispensing.

The packet should include a clinical note from within the past 12 months documenting measured height, weight, and calculated BMI. It should include the relevant ICD-10 diagnosis codes: E66.01 (morbid obesity due to excess calories), E66.09 (other obesity due to excess calories), or E66.9 (obesity, unspecified), plus any comorbidity codes such as E11.9 (type 2 diabetes mellitus without complications), I10 (essential hypertension), E78.5 (hyperlipidemia, unspecified), or G47.33 (obstructive sleep apnea). Lab results supporting comorbidity diagnoses should be included (HbA1c, fasting lipid panel, blood pressure log). The lifestyle intervention record demonstrating at least 90 days of structured behavioral or dietary program participation rounds out the clinical portion. A letter of medical necessity from the prescribing physician referencing the FDA approval for Wegovy, the STEP-1 trial outcomes, and the SELECT cardiovascular outcomes data should accompany the packet. Finally, include attestation that the patient has no personal or family history of medullary thyroid carcinoma or MEN2.

Submitting this packet as a single organized PDF rather than piecemeal fax pages reduces reviewer processing time and the likelihood that a document is missed during review.